PMH43 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED CENTRAL AND EASTERN EUROPEAN COUNTRIES
| Autor: | Balint Nemeth, R. Bendes, C. Croitoru, J. Kuchar, Balázs Nagy, B. Toth, Zoltán Vokó, Marek Psota, M. Bucek Psenkova, I.A. Deak, K Koczian, M. Tarhajova, M Horvath |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Cost–utility analysis
medicine.medical_specialty Risperidone business.industry 030503 health policy & services Health Policy Public Health Environmental and Occupational Health Cariprazine medicine.disease Eastern european 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry Schizophrenia medicine 030212 general & internal medicine 0305 other medical science Psychiatry business medicine.drug |
| Zdroj: | Value in Health. 21:S281-S282 |
| ISSN: | 1098-3015 |
| DOI: | 10.1016/j.jval.2018.09.1678 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect